Altimmune, Inc. (ALT)
- Previous Close
7.47 - Open
7.47 - Bid 7.55 x 1200
- Ask 7.58 x 1200
- Day's Range
7.47 - 8.23 - 52 Week Range
2.09 - 14.84 - Volume
3,126,273 - Avg. Volume
4,756,156 - Market Cap (intraday)
536.677M - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-1.66 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 20, 2017
- 1y Target Est
21.25
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
altimmune.comRecent News: ALT
Performance Overview: ALT
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALT
Valuation Measures
Market Cap
529.94M
Enterprise Value
332.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
934.32
Price/Book (mrq)
2.73
Enterprise Value/Revenue
781.22
Enterprise Value/EBITDA
-3.78
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.00%
Return on Equity (ttm)
-46.63%
Revenue (ttm)
426k
Net Income Avi to Common (ttm)
-88.45M
Diluted EPS (ttm)
-1.66
Balance Sheet and Cash Flow
Total Cash (mrq)
197.82M
Total Debt/Equity (mrq)
0.35%
Levered Free Cash Flow (ttm)
-49.98M